Replies to post #818150 on NorthWest Biotherapeutics Inc (NWBO)

[SkyLimit2022]

Gabagool,

“CAR T-cells, engineered T-cell therapy, adoptive cell therapy, all approved in some form or another on the basis of clear efficacy and outcomes improvement.“

I love that quote because dendritic cell platforms are emerging as potential COMBO agents for all of them, in addition to checkpoint inhibitors which are also approved & commercialized globally! 🌎

Proof of concept, & clinical validation of dendritic cell technology is really beginning to accelerate & become more visible, & several other researchers & companies are beginning to follow NWBO & join the R&D effort! For example, it appears that dendritic cell research is now beginning to expand beyond solid tumors to include blood cancers—that’s news!

1. This newly published clinical trial is for a blood cancer called multiple myeloma.

2. This new trial is for myeloid leukemia.



The field of immuno-oncology is advancing rapidly, with next-gen dendritic cell tech emerging as a key component in targeted, personalized, & less toxic NEXT-GEN COMBO therapies!


https://clinicaltrials.gov/study/NCT05378464

“They called me Gabagool Research”



AI Fact-Checking